Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Jim Cramer’s Best Performers List: Top 10 Stocks

Page 1 of 9

On Wednesday’s Mad Money episode, Jim Cramer took a deep dive into ten stocks, each worth over $1 billion, that have seen significant growth this year. While acknowledging that many of these stocks are speculative, he emphasized that they still hold potential as smart investments.

Cramer suggested that when looking back on this year, two trends will stand out: a steady rise in the S&P 500, and a series of moves that initially seemed almost magical, but were grounded in reality.

Cramer also reflected on the common investment approach of sticking with index funds, noting that it is a popular strategy because it requires minimal effort. But, according to him, simply parking your money in an index fund might not be the best way to maximize returns. Instead, he argued that investors should consider individual stocks with unique characteristics, many of which are speculative since they offer opportunities for much larger gains.

Cramer criticized the tendency among experts to dismiss individual stock investments beyond index funds, saying:

“Far too often we become snobs when we talk stocks. So many experts think that if you venture past the index, you could fall off some sort of intellectual cliff. It makes any gains null and void. It’s as if the huge swath of points you could have gained simply don’t count. But that, people, is nonsense.”

READ ALSO Jim Cramer on Microsoft and Other Stocks and 10 Stocks on Jim Cramer’s Radar

During Wednesday’s episode, Cramer highlighted several stocks that have surged by over 200% this year, choosing to focus only on those with a market cap of more than $1 billion. He did clarify, however, that he was not endorsing these stocks, especially given how much they have already appreciated. Instead, his point was that speculative stocks, despite their volatility, have a valid place in an investment portfolio.

While they come with risks, a small stake in one of these stocks could outperform a much larger investment in an index fund. For Cramer, it is not about avoiding speculative stocks altogether, but recognizing their potential when balanced alongside more stable investments like index funds.

Cramer wrapped up by stressing the importance of considering these high-flying, speculative stocks and said:

“The bottom line: Let’s remember this list of frothy stocks and think of them the next time you’re about to ignore a stock for being too speculative because these names are often the epitome of speculating wisely, which can be the key for terrific long-term performance, of course, only when melded with index funds.”

Jim Cramer’s List of 10 Stocks That Have Rallied Over 200% This Year

Our Methodology

For this article, we compiled a list of 10 stocks that were discussed by Jim Cramer during the episode of Mad Money on November 13 and listed the stocks in the order that Cramer mentioned them.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).

Jim Cramer’s List of 10 Stocks That Have Rallied Over 200% This Year

10. NuScale Power Corporation (NYSE:SMR

Cramer acknowledged that NuScale Power Corporation (NYSE:SMR) is spending a lot to develop nuclear reactors but went on to say that it has the possibility of raising money. Here’s what he had to say:

“Finally, the best performer: Viewers are crazy for nuclear power, you know that, you hear it all the time, but how about NuScale… This one’s on the come, so to speak because it’s losing a fortune, developing the nukes of the future, so-called small modular reactors. Yet it’s so beloved that I bet it can raise a ton of money once it lands a big hyperscaler contract. I’m clearly not alone here, the stock… is up 659% for the year.”

NuScale (NYSE:SMR) is a company specializing in the design and sale of modular light water reactor (LWMR) nuclear power plants. These reactors are intended for a variety of applications, including electricity generation, district heating, desalination, hydrogen production, and process heat. The company’s work aligns with broader national energy goals, as the White House recently outlined a roadmap aimed at significantly expanding nuclear energy production in the U.S.

By 2050, the administration plans to “at least” triple nuclear energy production, adding 200 gigawatts of new capacity. This ambitious expansion is seen as a means to create jobs, enhance energy reliability, and contribute to achieving a net-zero emissions economy by mid-century. In this context, SMRs, which the company specializes in, are expected to play a key role. The U.S. government has recognized the importance of advancing nuclear energy, with particular attention given to the development of small modular reactors.

The White House’s energy roadmap even specifically mentioned NuScale (NYSE:SMR) under the plan to expand nuclear energy. In particular, it noted how the U.S. Nuclear Regulatory Commission (NRC) is reforming its licensing and permitting processes to facilitate the deployment of new reactors. The company has been a significant part of this process, with its SMR design becoming the first to be certified by the NRC.

9. AppLovin Corporation (NASDAQ:APP)

Cramer highlighted AppLovin Corporation’s (NASDAQ:APP) recent earnings beat and mentioned the stock’s gains for the year during Mad Money’s episode.

“Not all these big speculative winners are money losers. Take AppLovin, which helps software developers create apps. While it’s been in business for 12 years, it still feels like AppLovin burst out of nowhere, doesn’t it? Reporting earnings of $434 million, analysts were expecting $319 million, that’s called a beat. It has mobile analytics and [an] in-house gaming division and it’s got an AI-powered acquisition platform that apparently everybody loves and that’s how you get more than 612% gain year to date. That’s right, 612% on a company that really isn’t all that speculative.”

AppLovin (NASDAQ:APP) provides software solutions that help advertisers optimize marketing and monetization, including tools for app measurement, analytics, and in-app bidding, while also operating a portfolio of free-to-play mobile games. Its business took a significant leap forward in 2023 with the launch of its Axon 2 advertising technology. Introduced in the second quarter of 2023, Axon 2 utilizes artificial intelligence to improve ad targeting and optimization, and its impact on the company has been notable.

As per its third-quarter earnings call, Axon 2’s self-learning capabilities, combined with ongoing updates from the company’s engineering team, have significantly improved the platform’s performance. Management highlighted that these advancements led to a notable step change in growth, with Axon 2 being the primary driver behind the company’s success in the quarter.

As a result of the improved technology, AppLovin’s (NASDAQ:APP) software platform revenue surged by 66%, reaching $835 million for the third quarter. In contrast, the company’s legacy apps business, which consists of its portfolio of gaming apps, saw more modest growth, with revenue increasing by just 1% to $363 million.

Page 1 of 9

AI Fire Sale: Insider Monkey’s #1 AI Stock Pick Is On A Steep Discount

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!

The whispers are turning into roars.

Artificial intelligence isn’t science fiction anymore.

It’s the revolution reshaping every industry on the planet.

From driverless cars to medical breakthroughs, AI is on the cusp of a global explosion, and savvy investors stand to reap the rewards.

Here’s why this is the prime moment to jump on the AI bandwagon:

Exponential Growth on the Horizon: Forget linear growth – AI is poised for a hockey stick trajectory.

Imagine every sector, from healthcare to finance, infused with superhuman intelligence.

We’re talking disease prediction, hyper-personalized marketing, and automated logistics that streamline everything.

This isn’t a maybe – it’s an inevitability.

Early investors will be the ones positioned to ride the wave of this technological tsunami.

Ground Floor Opportunity: Remember the early days of the internet?

Those who saw the potential of tech giants back then are sitting pretty today.

AI is at a similar inflection point.

We’re not talking about established players – we’re talking about nimble startups with groundbreaking ideas and the potential to become the next Google or Amazon.

This is your chance to get in before the rockets take off!

Disruption is the New Name of the Game: Let’s face it, complacency breeds stagnation.

AI is the ultimate disruptor, and it’s shaking the foundations of traditional industries.

The companies that embrace AI will thrive, while the dinosaurs clinging to outdated methods will be left in the dust.

As an investor, you want to be on the side of the winners, and AI is the winning ticket.

The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI.

From computer scientists to mathematicians, the next generation of innovators is pouring its energy into this field.

This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements.

By investing in AI, you’re essentially backing the future.

The future is powered by artificial intelligence, and the time to invest is NOW.

Don’t be a spectator in this technological revolution.

Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation.

This isn’t just about making money – it’s about being part of the future.

So, buckle up and get ready for the ride of your investment life!

Act Now and Unlock a Potential 10,000% Return: This AI Stock is a Diamond in the Rough (But Our Help is Key!)

The AI revolution is upon us, and savvy investors stand to make a fortune.

But with so many choices, how do you find the hidden gem – the company poised for explosive growth?

That’s where our expertise comes in.

We’ve got the answer, but there’s a twist…

Imagine an AI company so groundbreaking, so far ahead of the curve, that even if its stock price quadrupled today, it would still be considered ridiculously cheap.

That’s the potential you’re looking at. This isn’t just about a decent return – we’re talking about a 10,000% gain over the next decade!

Our research team has identified a hidden gem – an AI company with cutting-edge technology, massive potential, and a current stock price that screams opportunity.

This company boasts the most advanced technology in the AI sector, putting them leagues ahead of competitors.

It’s like having a race car on a go-kart track.

They have a strong possibility of cornering entire markets, becoming the undisputed leader in their field.

Here’s the catch (it’s a good one): To uncover this sleeping giant, you’ll need our exclusive intel.

We want to make sure none of our valued readers miss out on this groundbreaking opportunity!

That’s why we’re slashing the price of our Premium Readership Newsletter by a whopping 70%.

For a ridiculously low price of just $29, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single restaurant meal!

Here’s why this is a deal you can’t afford to pass up:

• Access to our Detailed Report on this Game-Changing AI Stock: Our in-depth report dives deep into our #1 AI stock’s groundbreaking technology and massive growth potential.

• 11 New Issues of Our Premium Readership Newsletter: You will also receive 11 new issues and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan.

• One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149

• Bonus Reports: Premium access to members-only fund manager video interviews

• Ad-Free Browsing: Enjoy a year of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.

• 30-Day Money-Back Guarantee:  If you’re not absolutely satisfied with our service, we’ll provide a full refund within 30 days, no questions asked.

 

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $29.

2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!


No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a year later!

Penicillin Changed the World. This Drug Could Too

This Clinical-stage Biotech Company is Taking a Revolutionary Approach to Eradicating Many Respiratory Viruses Including a single drug to treat COVID, RSV, FLU and even Monkey-pox!

This is a clinical-stage, global leader in broad-spectrum antiviral nanomedicines who is developing therapeutic drugs that work safely and effectively, even against emerging variants!

A novel broad-spectrum antiviral

NV-387,  a drug that  treats RSV, COVID-19, Long COVID, Influenza, Bird Flu H5N1, and other respiratory viral infections as well as Monkey-pox, has successfully completed Phase 1 clinical trials in healthy subjects with no reported adverse events, even at the highest and repeated dosages. Remarkably, the company has been able to develop NV-387 for oral administration already, as well as for injectable and inhalation formulations to enable many modes of use. The Company is currently focused on advancing NV-387 into Phase II human clinical trials for the treatment of RSV infection.

Susceptible viruses CANNOT escape NV-387, even as they continue to evolve in the field into variants. Why? Because  no matter how much the virus changes, it continues to use the same host-side signature to bind to and cause infection in the hosts, and thus the nanoviricide would be anticipated to continue to be effective even as the virus mutates to generate variants.

Click to continue reading…